1G. D. Schmidt-Wolf,R. S. Negrin,I. G. H. Schmidt-Wolf. Activated T cells and cytokine-induced CD3+CD56+ killer cells[J] 1997,Annals of Hematology(2):51～56
2C. Mathiot,J. -L. Teillaud,M. Elmalek,V. Mosseri,L. Euller-Ziegler,A. Daragon,B. Grosbois,J. -L. Michaux,T. Facon,J. -F. Bernard,B. Duclos,M. Monconduit,W. H. Fridman. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma[J] 1993,Journal of Clinical Immunology(1):41～48
同被引文献12
1Treon SP, ShimaY, Grossbard ML, etal. Treat of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens[J]. Annal Oncol, 2000, 11(Suppl 1): 107- 111.
2Treon SP, Raje N, Anderson KK. Immunotherapyeutic strategies for the treatment of plasma cell malignancies[J]. Semin Oncol, 2000, 27(5): 598- 613.
3Rgicles H, Olive C, Flgnu M. A serum - free culture method for myeloma progenitors in vitro: proliferative and immunophenotypic characteristics[ J]. Exp Hematol, 1990, 18(2):79-83.
4Grub L, White CA, Dallarie, et al. Curr- pharm rituxinab:the first monoclonal antibody approved for the treatment of lymphoma[J]. Biatechenl, 2000, 1(1): 1-9.
5Grillo AJ. Rituximab: an insider's historical prospective[J].Semin Oncol, 2000, 2(Suppl 12): 9-46.
6David G, Kathleen D, Ferry J. Antibody therapy for treatment of multiple myeloma[J]. Semin Hematal, 1999, 36(Suppl 1): 30 - 33.
7Josee G, Luisella Z, Thomas V, et al. Biologic response of B lymphoma cells to anti - CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement - mediated cell lysis[J]. Blood, 2000,95(12):3900- 3908.
8Josee G, Maneula L, Valeria F, et al. CD20 level determine the in vitro susceptibility to rituximab and complement of B -cell chronic lymphocytic leukemia: further regulation by CD55 and CD59[J]. Blood, 2001,98(12): 3383 - 3389.
10S. P. Treon,Y. Shima,M. L. Grossbard,F. I. Preffer,A. R. Belch,L. M. Pilarski,K. C. Anderson. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens[J] 2000,Annals of Oncology(1):107～111
